The findings suggest sex impacts clinical interpretation of plasma p-tau181, but the authors explicitly state this needs replication and has important implications for biomarker use. Clear guidance on sex-stratified interpretation is needed for clinical implementation. Gap type: open_question Source paper: Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. (2022, Molecular psychiatry, PMID:35768637)
Landscape Summary: Should sex-specific cutoff values be established for plasma p-tau181 in clinical practice and trials? is a 0.84 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Should sex-specific cutoff values be established for plasma p-tau181 in clinical practice and trials? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: